Latest News from Pro PG

Sourcing a medicine is only the first step in Australian market access. See how ProPG supports pharmaceutical companies across access pathways, import coordination, cold-chain storage and hospital distribution.

Pro Pharmaceuticals Group will attend CPHI Milan 2026 from 6–8 October, with a focus on European RLD, reference medicinal product, comparator and clinical-trial sourcing.

A practical guide to RLD, reference medicinal product and comparator sourcing from Europe for clinical trials, bioequivalence studies and generic development.

When a medicine becomes unavailable in Australia, several access pathways may be relevant. This guide explains Section 19A, SAS Categories A, B and C, Authorised Prescriber and the practical realities of sourcing overseas medicines.

Pro Pharmaceuticals Group has incorporated DHL Express GoGreen Plus into its international pharmaceutical logistics operations, supporting a more sustainable approach to medicine supply across Australia, Europe and global markets.

Pro Pharmaceuticals Group will attend Expopharm Munich 2026 from 15–17 September to strengthen European pharmaceutical sourcing partnerships and discuss medicine shortages, Section 19A, SAS and international medicine supply.

Section 19A and the Special Access Scheme are both routes to medicines that aren't on the ARTG — but they exist for different reasons and are triggered by different people. Here's how hospital pharmacists, procurement teams and pharmaceutical companies can tell which pathway applies, and why the distinction matters for supply planning.

Pro Pharmaceuticals Group supports Australian hospitals and pharmaceutical partners with critical medicine access, medicine shortages, TGA Section 19A and SAS pathways, comparator sourcing and global clinical trial supply.